Qlife Advances Two Home Diagnostic Tests for Heart Failure into Clinical Trials
核心洞察
Qlife Holding AB (搜索) and partner Hipro Biotechnology (搜索) are advancing nt-proBNP (搜索) and potassium biomarker tests into clinical trials for congestive heart failure monitoring.
The development addresses a significant unmet need as no approved home self-tests currently exist for heart failure monitoring, requiring patients to visit laboratories for blood testing.
Heart failure affects an estimated 64 million people globally, with contributing factors including aging populations and increased survival rates post-heart attack.
Qlife Holding AB (搜索), a Swedish company pioneering clinical-grade home diagnostics, announced it is advancing two biomarker tests for congestive heart failure monitoring into clinical trials. The company, in partnership with Hipro Biotechnology (搜索), will evaluate nt-proBNP (搜索) and potassium tests designed for home use, addressing a significant gap in current heart failure management.
The development comes as global In Vitro Diagnostic (IVD) companies show increasing interest in the home testing market, with Qlife planning to partner this product line during or after the clinical trial phase. The collaboration also supports ongoing merger activities between Qlife and Hipro Biotechnology (搜索).
Addressing Critical Healthcare Gap
Heart failure represents a substantial public health challenge, with an estimated global prevalence of 64 million people. Currently, no approved home self-tests are available for monitoring heart failure, requiring patients to visit laboratories for blood testing. This creates barriers to regular monitoring for vulnerable patients who could benefit from staying at home while maintaining access to essential clinical blood testing.
"We are very happy to advance our strategy of introducing significant biomarker tests for home use that address critical medical conditions," stated Thomas Warthoe, CEO of Qlife. "With the successful validation of our Egoo Health platform for immunodiagnostics through the PHE test, we are poised to enter a much broader market with two new tests targeting heart failure."
Clinical Development Strategy
The advancement into clinical trials follows Qlife's successful clinical documentation of the self-test PHE for the rare disease Phenylketonuria, which is progressing towards regulatory approval under EU IVD Regulation. This experience provides a foundation for the heart failure testing program.
Upon completion of clinical documentation, Qlife plans to submit applications for nt-proBNP (搜索) and potassium tests for approval in the European Union, China, and the United States. The company anticipates high demand for congestive heart failure self-tests across all these markets.
Growing Market Need
The expanding prevalence of heart failure stems from multiple factors, including an aging population, increased survival rates post-heart attack, and improvements in treatment and patient outcomes. These trends create a heightened need for decentralized and at-home monitoring solutions.
Warthoe emphasized that as healthcare resources face increasing demands, the company's solutions offer vulnerable patients the ability to remain at home while maintaining access to essential clinical blood testing. The Egoo Health platform has been successfully validated for immunodiagnostics, positioning the company to address broader market opportunities in cardiovascular monitoring.